Mexico Approves RSV Vaccine for Pregnant Women and Older Adults
New Vaccine Offers Protection Against RSV for Infants and seniors
mexico City, Mexico – In a critically important advancement for public health, Mexico’s Federal Commission for teh Protection against Sanitary Risks (COFEPRIS) has approved a new vaccine against respiratory syncytial virus (RSV) for use in pregnant women and adults over 60. This groundbreaking vaccine offers a crucial layer of protection against a virus that can cause serious illness in vulnerable populations.
The bivalent, recombinant RSV vaccine can be administered to pregnant women between 32 and 36 weeks of gestation. A single intramuscular injection provides passive immunity to infants from birth to six months old, considerably reducing their risk of severe RSV infection. The vaccine is also approved for adults aged 60 and older,who are also susceptible to serious complications from RSV.
“RSV is a common cause of respiratory illness in children, and infants are particularly vulnerable to severe complications like pneumonia and bronchiolitis,” said Dr. [Insert Name], a leading infectious disease specialist. “This new vaccine offers a vital tool to protect our youngest and most vulnerable citizens.”
RSV typically causes cold-like symptoms, but in infants and older adults, it can led to hospitalization and even death. According to the U.S. Centers for Disease Control and Prevention (CDC), up to 3% of infants infected with RSV require hospitalization each year.
The CDC estimates that RSV is responsible for 100 to 300 deaths in children under five and 6,000 to 10,000 deaths in adults over 65 annually in the United States. In Mexico, during the 50th epidemiological week of the 2024-2025 season, RSV accounted for 44.7% of confirmed cases of respiratory infections.
Prior to this vaccine, the only available preventative measure for infants was palivizumab, a monoclonal antibody treatment administered after birth. This new vaccine offers a proactive approach to RSV prevention,providing protection from the moment of birth.
the approval of this RSV vaccine marks a major step forward in protecting vulnerable populations from this perhaps deadly virus.
new RSV Vaccine Offers Protection for Infants and Seniors
Mexico City, Mexico – A new vaccine offering critical protection against respiratory syncytial virus (RSV) has been approved for use in pregnant women and adults over 60 by Mexico’s Federal Commission for the Protection against Sanitary Risks (COFEPRIS).this bivalent, recombinant RSV vaccine represents a major advancement in public health, offering a much-needed shield against a virus that can cause severe illness in vulnerable populations.
The vaccine can be administered to pregnant women between 32 and 36 weeks of gestation via a single intramuscular injection. This provides passive immunity to infants from birth to six months old, significantly decreasing their risk of severe RSV infection. Additionally, the vaccine is approved for adults aged 60 and older, who are also at increased risk of serious complications from RSV.
“RSV is a common cause of respiratory illness in children, and infants are particularly vulnerable to severe complications like pneumonia and bronchiolitis,” said Dr. [Insert Name], a leading infectious disease specialist.”This new vaccine offers a vital tool to protect our youngest and most vulnerable citizens.”
While RSV frequently enough presents with cold-like symptoms, it can lead to hospitalization and even death in infants and older adults. Statistics paint a grim picture: up to 3% of infants infected with RSV require hospitalization annually according to the U.S. Centers for Disease Control and Prevention (CDC). The CDC estimates that RSV is responsible for 100 to 300 deaths in children under five and 6,000 to 10,000 deaths in adults over 65 annually in the United States. In Mexico, RSV accounted for 44.7% of confirmed respiratory infection cases during the 50th epidemiological week of the 2024-2025 season.
Prior to this vaccine, the only preventative measure for infants was palivizumab, a monoclonal antibody treatment given after birth. This new vaccine allows for a proactive approach to RSV prevention, providing protection from the moment of birth.